Leerink Partners Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Announces Target Price $52
William Blair Maintains PTC Therapeutics(PTCT.US) With Buy Rating
Positive Outlook for PTC Therapeutics: Buy Rating Affirmed Amid European and U.S. Approval Prospects for Sephience
RBC Capital Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $65
RBC Capital Reiterates Outperform on PTC Therapeutics, Maintains $65 Price Target
PTC Therapeutics Analyst Ratings
BofA Securities Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Maintains Target Price $55
Cautious Hold Rating for PTC Therapeutics Amidst FDA Reviews and Revenue Uncertainties
Wells Fargo Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $68
Analysts' Opinions Are Mixed on These Healthcare Stocks: PTC Therapeutics (PTCT) and Qiagen (QGEN)
RBC Capital Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $65
RBC Lifts Price Target on PTC Therapeutics to $65 From $64, Keeps Outperform Rating
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Nanobiotix (NBTX) and PTC Therapeutics (PTCT)
Wells Fargo Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $68
Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT) and Rhythm Pharmaceuticals (RYTM)
J.P. Morgan Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $75
PTC Therapeutics Is Maintained at Overweight by JP Morgan
PTC Therapeutics Analyst Ratings
TD Cowen Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Maintains Target Price $60
William Blair Maintains PTC Therapeutics(PTCT.US) With Buy Rating